Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Vitolo

Showing results (51-60 of 212) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|July 25, 2017
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 studyLuciano Cascione, Andrea Rinaldi, Annalisa Chiappella, et al.
Journal of Hematology & Oncology|June 8, 2020
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYALaurie H Sehn, Maurizio Martelli, Marek Trněný, et al.
Haematologica|January 26, 2006
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow TransplantationGiovanni Barosi, Angelo Carella, Mario Lazzarino, et al.
Cancer|January 15, 2008
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphomaPier Luigi Zinzani, Monica Tani, Stefano Fanti, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
Future Oncology (London, England)|April 19, 2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 20, 2022
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYAIrene Canales Ruiz, Maurizio Martelli, Laurie H Sehn, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2014
Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphomaAndrea Riccardo Filippi, Patrizia Ciammella, Cristina Piva, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2014
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)Corrado Tarella, Luca Arcaini, Luca Baldini, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Pageof 22

Showing results (51-60 of 212) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|July 25, 2017
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 studyLuciano Cascione, Andrea Rinaldi, Annalisa Chiappella, et al.
Journal of Hematology & Oncology|June 8, 2020
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYALaurie H Sehn, Maurizio Martelli, Marek Trněný, et al.
Haematologica|January 26, 2006
Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow TransplantationGiovanni Barosi, Angelo Carella, Mario Lazzarino, et al.
Cancer|January 15, 2008
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphomaPier Luigi Zinzani, Monica Tani, Stefano Fanti, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
Future Oncology (London, England)|April 19, 2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Thomas E Witzig, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 20, 2022
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYAIrene Canales Ruiz, Maurizio Martelli, Laurie H Sehn, et al.
International Journal of Radiation Oncology, Biology, Physics|March 12, 2014
Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphomaAndrea Riccardo Filippi, Patrizia Ciammella, Cristina Piva, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 11, 2014
Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)Corrado Tarella, Luca Arcaini, Luca Baldini, et al.
Blood|July 12, 2013
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)John Radford, Andrew Davies, Guillaume Cartron, et al.
Pageof 22